Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichwark, PhD, has been named the company's CEO.

The company leverages artificial intelligence to screen for liver and kidney disease, as well as other chronic conditions that cause progressive organ damage. The company has plans to penetrate new markets and serve patients and physicians directly and through strategic partnerships. Fibronostics is a global diagnostics company, providing non-invasive, algorithmic diagnostics and insights to detect and manage organ lesions caused by metabolic diseases.

Fibronostics Secures Financing, Announces New Ceo

Description

Company Information

FundzWatch™ Score

Buyer Intent Analysis

Fibronostics Secures Financing, Announces New Ceo

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

FundzWatch™ Score

Buyer Intent Analysis

Company Information